EVEREST MED Achieves Favorable Outcome in Patent Protection for Nefecon®

Stock News

02/27

On February 27, EVEREST MED (01952) announced a significant development in the patent protection of its innovative product, budesonide enteric-coated capsules (Nefecon®). The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's application for pre-litigation conduct preservation. The court ordered relevant generic drug manufacturers to immediately cease infringement activities and withdraw their products from public procurement lists. The ruling took effect immediately upon issuance. EVEREST MED welcomed the court's fair decision and stated it will continue to protect intellectual property rights in accordance with the law, promoting access to innovative therapies for more patients.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1113601668"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113601668\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113601668?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 15:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113601668","market":"sh","top_or_hot":-1,"title":"EVEREST MED Achieves Favorable Outcome in Patent Protection for Nefecon®","media":"Stock News","content":"<p>On February 27, EVEREST MED (01952) announced a significant development in the patent protection of its innovative product, budesonide enteric-coated capsules (Nefecon®). The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's application for pre-litigation conduct preservation. The court ordered relevant generic drug manufacturers to immediately cease infringement activities and withdraw their products from public procurement lists. The ruling took effect immediately upon issuance. EVEREST MED welcomed the court's fair decision and stated it will continue to protect intellectual property rights in accordance with the law, promoting access to innovative therapies for more patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EVEREST MED Achieves Favorable Outcome in Patent Protection for Nefecon®</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEVEREST MED Achieves Favorable Outcome in Patent Protection for Nefecon®\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-02-27 15:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On February 27, EVEREST MED (01952) announced a significant development in the patent protection of its innovative product, budesonide enteric-coated capsules (Nefecon®). The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's application for pre-litigation conduct preservation. The court ordered relevant generic drug manufacturers to immediately cease infringement activities and withdraw their products from public procurement lists. The ruling took effect immediately upon issuance. EVEREST MED welcomed the court's fair decision and stated it will continue to protect intellectual property rights in accordance with the law, promoting access to innovative therapies for more patients.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1113601668","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113601668","pubTimestamp":1772177554,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On February 27, EVEREST MED (01952) announced a significant development in the patent protection of its innovative product, budesonide enteric-coated capsules (Nefecon®). The Guangzhou Intellectual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01952":"云顶新耀","BK1583":"高瓴概念","BK1574":"生物医药B类股"},"translate_title":"EVEREST MED在Nefecon专利保护方面取得良好成果®","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"On February 27, EVEREST MED (01952) announced a significant development in the patent protection of its innovative product, budesonide enteric-coated capsules (Nefecon®). The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's application for pre-litigation conduct preservation. The court ordered relevant generic drug manufacturers to immediately cease infringement activities and withdraw their products from public procurement lists. The ruling took effect immediately upon issuance. EVEREST MED welcomed the court's fair decision and stated it will continue to protect intellectual property rights in accordance with the law, promoting access to innovative therapies for more patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}